FDA Sets Adcomm Meeting to Assess Checkpoint Inhibitors in Stomach Cancer Using PD-L1

The Oncologic Drugs Advisory Committee in a Sept. 26 meeting will discuss whether the regulator should restrict approval of checkpoint inhibitors based on PD-L1 expression levels.